91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In an interview with Contract Pharma, 91黑料’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
91黑料’s Simon Bruce, Vice President of Internal Medicine and Drug Development Solutions sits down for a Q&A with Pharmaceutical Executive and gives an overview on the obesity survey carried out by 91黑料 in January 2024 and what it suggests about the state of the obesity-related pipeline.
-
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
This news piece from The Clinical Trial Vanguard provides an overview of the findings from 91黑料’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
This news article, from Applied Clinical Trials, outlines findings from 91黑料’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
David T. Novotny, General Manager & Global Head of 91黑料’s Medical Device and Diagnostic Research business unit, considers .
